EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Radiofrequency Ablation and Immunotherapy: Orchestrating the Immune Microenvironment for Improved Hepatocellular Carcinoma Control

Liu Yang iD, Shuhang Wei, Zongxin Liu, Qiqi Liu, Zhen Yu, Yuemin Feng, Qiang Zhu

Immunology · 2025

DOI: 10.1111/imm.70004 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Immunology, 2025. Verfasst von Liu Yang und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology, Shandong Provincial Hospital, Shandong University, Jinan, Shandong, China. Hauptthemen laut MEDLINE: Carcinoma, Hepatocellular, Liver Neoplasms, Tumor Microenvironment, Radiofrequency Ablation. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 102 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Science and Technology Department of Xinjiang Uygur Autonomous Region, Science and Technology Bureau of Xinjiang Production and Construction Corps.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Radiofrequency ablation (RFA) is a radical treatment modality for early‐stage hepatocellular carcinoma (HCC). In addition to directly eliminating tumour cells, RFA induces changes in infiltrating cells within the liver tumour immune microenvironment (TIME), thereby eliciting anti‐tumour immune effects. Moreover, incomplete radiofrequency ablation (IRFA) induces an immunosuppressive tumour microenvironment, which inhibits anti‐tumour immune responses and promotes tumour recurrence and metastasis. Immunotherapy, a systemic treatment, activates or enhances the immune system to recognise and eliminate tumour cells. Thus, orchestrating the TIME makes it possible to combine RFA and immunotherapy, which may significantly enhance the anti‐tumour immune response to target residual tumour cells. This combinatorial approach may emerge as a pivotal strategy to augment HCC control and mitigate post‐RFA recurrence. This review discusses how RFA modulates the TIME in HCC, and the immune‐related mechanisms leading to tumour cell survival and invasion after IRFA. Finally, we summarise the combined mechanisms of the two modalities on TIME, and their clinical implications for treating HCC, aiming to provide new insights for the combined strategy of RFA and immunotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, HepatocellularLiver NeoplasmsTumor MicroenvironmentRadiofrequency AblationImmunotherapyHumansAnimalsCombined Modality TherapyNeoplasm Recurrence, Local

Stichwörter der Autor:innen

combined therapyhepatocellular carcinomaimmunotherapyradiofrequency ablationtumour immune microenvironment

Autor:innen und Institutionen

  • Department of Gastroenterology, Shandong Provincial Hospital, Shandong University, Jinan, Shandong, China.
  • Department of Gastroenterology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, Shandong, China.
  • Department of Infectious Disease, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, China.

ORCID-Profile: Liu Yang

Förderung

  • National Natural Science Foundation of China
  • Science and Technology Department of Xinjiang Uygur Autonomous Region
  • Science and Technology Bureau of Xinjiang Production and Construction Corps
  • Natural Science Foundation of Shandong Province
  • Xinjiang Science and Technology Department

Zitieren

APA

Yang, L., Wei, S., Liu, Z., Liu, Q., Yu, Z., Feng, Y., & Zhu, Q. (2025). Radiofrequency Ablation and Immunotherapy: Orchestrating the Immune Microenvironment for Improved Hepatocellular Carcinoma Control. Immunology. https://doi.org/10.1111/imm.70004

Vancouver

Yang L, Wei S, Liu Z, Liu Q, Yu Z, Feng Y, et al. Radiofrequency Ablation and Immunotherapy: Orchestrating the Immune Microenvironment for Improved Hepatocellular Carcinoma Control. Immunology. 2025. doi:10.1111/imm.70004

BibTeX
@article{Yang2025,
  author = {Yang, Liu and Wei, Shuhang and Liu, Zongxin and Liu, Qiqi and Yu, Zhen and Feng, Yuemin and Zhu, Qiang},
  title = {Radiofrequency Ablation and Immunotherapy: Orchestrating the Immune Microenvironment for Improved Hepatocellular Carcinoma Control},
  journal = {Immunology},
  year = {2025},
  doi = {10.1111/imm.70004}
}
Kostenlos starten →